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Osteoarthritis (OA) is the most prevalent musculoskeletal disease and a leading 26 
cause of disability worldwide. OA mostly affects the population aged over 50 27 
years and it is estimated that the population with OA will double in the next 30 28 
years. The pathogenesis of OA is a complex process that involves the entire 29 
joint. The pathological cascade of events in OA occur at the molecular, cellular 30 
and tissue level and not only involve cartilage degradation but also sub-31 
chondral sclerosis, synovial inflammation as well as damage to other joint 32 
structures such as ligaments and menisci, causing pain and loss of articular 33 
function (1). Although the cartilage degradation is not the only event responsible 34 
for joint degradation its role in OA pathogenesis continuous to be relevant. One 35 
factor that contributes to the pathological cascades is the imbalance between 36 
apoptosis and autophagy in the articular cartilage (1). 37 
 38 
Mitochondria are currently in the focus of biomedical research due to 39 
their role in aging and in the development of human pathologies (2). 40 
Mitochondria are the organelles that convert the nutritional molecules into 41 
adenosine triphosphate (ATP), generating most of the energy necessary for the 42 
cell. Mitochondrial dysfunction causes a series of metabolic alterations that lead 43 
to an increase in the production of reactive oxygen species (ROS) and 44 
decreasing ATP and oxygen consumption. Mitochondrial dysfunction causes 45 
also an inflammatory response inducing synthesis of cytokines and MMPs. 46 
Mitochondria contain their own genetic material, mtDNA; mtDNA has a high 47 
mutation rate, due to the absence of an effective system of repair and its 48 
proximity to the main source of ROS production in the cell, the electron 49 
transport chain. 50 
 51 
Increasing evidence suggests that mitochondria are involved in the 52 
pathogenesis of OA (3). Analyses of mitochondrial function in OA chondrocytes 53 
reveal decreased activity of the mitochondrial respiratory complexes II and III as 54 
well as increased mitochondrial mass, compared to healthy chondrocytes. 55 
Mitochondrial dysfunction can contribute to cartilage degeneration in OA. 56 
Increased ROS production, impaired anabolic and growth responses of 57 
chondrocytes, excessive and reduced chondrocyte apoptosis and autophagy 58 
respectively, and enhanced inflammatory responses are particularly important. 59 
Compared to normal cartilage, OA chondrocytes fail to generate energy and 60 
mitochondrial biogenesis is altered. All the data suggest that mitochondria and 61 
mitochondrial function needs to be regulated in order to prevent the generation 62 
of high levels of ROS and oxidative stress.  63 
 64 
Autophagy, which is activated under hypoxic and energy stress to 65 
provide energy for the cell, is a key regulator of cellular homeostasis through 66 
the removal of damaged macromolecules and organelles, including 67 
mitochondria (4). Mitophagy is the elimination of depolarized/damaged 68 
mitochondria. Pharmacological activation of autophagy in chondrocytes 69 
significantly protected against mitochondrial dysfunction suggesting that 70 
mitophagy may function to eliminate damage/dysfunctional mitochondria in 71 
chondrocytes and prevent oxidative stress (4). Studies in human chondrocytes 72 
showed that activation of autophagy is critical in protecting against 73 
mitochondrial dysfunction (5). Moreover, the mammalian target of rapamycin 74 
inhibitor DNA damage-inducible transcript 4 protein (DDIT4, also known as 75 
REDD1) is a key mediator of cartilage homeostasis through the regulation of 76 
autophagy and mitochondrial biogenesis; expression of DDIT4 is decreased in 77 
OA cartilage, and deficiency of this protein exacerbates the severity of injury-78 
induced OA (6).  79 
 80 
In this issue of Osteoarthritis and Cartilage, Ansari MY et al. suggest that 81 
Parkin-mediated mitophagy is an important mechanism to limit ROS production 82 
and improve OA chondrocyte survival under pathological conditions (7). Parkin 83 
is an E3 ubiquitin ligase; it is selectively recruited to dysfunctional mitochondria 84 
with low membrane potential. After recruitment, Parkin mediates the engulfment 85 
of mitochondria by autophagosomes and the selective elimination of impaired 86 
mitochondria. Authors propose that increased expression of Parkin might be 87 
involved in the clearance of damaged mitochondria and indeed OA 88 
chondrocytes with depleted Parkin expression showed increased production of 89 
ROS, accumulation of dysfunctional mitochondria, and apoptosis. These 90 
authors speculate that loss of Parkin function could contribute directly to the 91 
pathogenesis of OA. 92 
 93 
The interaction between Parkin and mitochondrial NAD-dependent 94 
protein deacetylase sirtuin 3 (SIRT-3) is a very interesting aspect to understand 95 
the relevance of the results reported by Ansary MY et al. SIRT-3, the chief 96 
deacetylase mitochondrial protein, has been shown to mediate age-related 97 
changes in cartilage redox regulation; this action protected against early-stage 98 
OA in rats and SIRT-3 has been described as a metabolic sensor that responds 99 
to changes in the energetic state of the cell through oxidized nicotinamide 100 
adenine dinucleotide, to regulate mitochondrial acetylation and protect against 101 
mitochondrial damage. SIRT-3 activates mitophagy and its deficiency impairs 102 
mitophagy by increasing acetylation of Pink/Parkin and decreasing Parkin 103 
expression (8) (Figure 1).   104 
 105 
Mitochondrial dysfunction has also been associated with a disbalance 106 
between ROS production and expression of superoxide dismutase 2 (SOD2), 107 
the major mitochondrial antioxidant protein. Downregulation of SOD2 has been 108 
reported in OA chondrocytes (9). Levels of this enzyme are decreased in the 109 
superficial layer of OA cartilage and markedly down-regulated in end-stage OA 110 
cartilage. Both SOD2 and SIRT-3 activity decreased with age in cartilage and 111 
treatment with SIRT-3 increased SOD2 activity suggesting that SIRT-3 could 112 
mediate age-related changes in cartilage redox regulation and protect against 113 
OA by rescuing acetylation-dependent inhibition of SOD2 activity (10).  114 
 115 
The proposed theory for the participation of mitochondria in OA suggests 116 
that dysfunction of the mitochondrial respiratory complex leads to increased 117 
production of ROS, resulting in mtDNA damage followed by mutations that 118 
compromise mitochondrial protein function and further increase production of 119 
ROS and reactive nitrogen species (RNS). mtDNA shows very high mutation 120 
and sequence evolution rates. The accumulated mtDNA mutations throughout 121 
evolution persist today as high frequency continent-specific mtDNA 122 
polymorphisms and are called haplogroups (11, 12). Specific mtDNA 123 
haplogroups have been consistently linked with a wide spectrum of diseases, 124 
including OA. Evidence has accumulated from a series of studies for an 125 
association between mtDNA haplogroups and prevalence, incidence and 126 
progression of OA in different cohorts of patients (13, 14). In terms of a direct 127 
relationship between mtDNA damage and haplogroups, greater damage could 128 
be expected in those haplogroups associated with increased ROS production. 129 
mtDNA haplogroups H and J have been found to differ in the gene expression 130 
and activity of SIRT-3 under simulated mild oxidative stress conditions using 131 
transmitochondrial cybrids, where H cybrids showed higher SIRT-3 activity and 132 
expression than J cybrids (15). These data suggest that mtDNA mutations and 133 
variants could modulate mitophagy through their capacity to regulate different 134 
nuclear target genes such as SIRT-3 and NAD-dependent protein deacetylase 135 
sirtuin-1 (SIRT1). SIRT1 is involved in mitochondria biogenesis inducing the 136 
expression of –peroxisome proliferator-activated receptor γ co-activator 1α 137 
(PGC-1α; the so-called master regulator of mitochondrial biogenesis) (16). 138 
 139 
A decreased capacity for mitochondrial biogenesis in chondrocytes is 140 
linked to reduced AMP-activated protein kinase (AMPK) activity and decreased 141 
expression of SIRT1, PGC1α; TFAM (transcription factor A, mitochondrial), 142 
nuclear respiratory factor 1 (NRF1) and NRF2 (16). AMPK is a key molecule 143 
associated with metabolism in chondrocytes that regulates energy metabolism 144 
through the downstream mediators such as SIRT1 and mechanistic target of 145 
rapamycin (mTOR) (17). Activation of the AMPK–SIRT1–PGC1α pathway 146 
increases mitochondrial biogenesis in chondrocytes, limiting OA progression. 147 
Furthermore, deficiency in AMPK and SIRT1 modulates PGC1α activity, leading 148 
to reduced oxidative stress and procatabolic responses in chondrocytes from 149 
patients with OA (16). 150 
 151 
All these results open a wide new spectrum of therapeutic approaches 152 
with the common goal of restoring mitochondrial function in chondrocytes and 153 
reducing the mitochondrial stress. Some new potential therapies could be: 1) To 154 
activate the AMPK-SIRT-3 pathway in order to induce Parkin expression and 155 
mitophagy 2) To activate the AMPK-SIRT-3 pathway in order to induce SOD2 156 
activity a reducing Mitochondrial stress. 3) Activation of the AMPK–SIRT1–157 
PGC1α pathway to promote mitochondrial biogenesis, 4) The development of 158 
cellular therapy using cells with harboring “good mitochondria”, or even the 159 
administration of isolated “good mitochondria” into the osteoarthritic joint. 160 
 161 
In summary, the study of Ansary MY et al. is in line with other published 162 
results that confirm the relevant role of mitochondrial activity and function in the 163 
process of articular cartilage degradation and in the pathogenesis of OA. In 164 
particular, some molecules such as AMPK, Parkin, SIRT-1, SIRT-3 and PGC1-165 
alpha may represent therapeutic targets for modulating mitophagy and 166 
mitochondrial biogenesis, which may represent new therapeutic alternatives in 167 
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Figure 1: AMPK-SIRT-PARKIN pathway in OA chondrocytes. Hypothetical 277 
view on the key role of AMPK-SIRT-Parkin in regulating mitochondrial function 278 
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